The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1998 • 5,487 citations

Cloning of a novel receptor expressed in rat prostate and ovary.

1996 • 4,782 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Molecular basis of agonism and antagonism in the oestrogen receptor

1997 • 3,285 citations

The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen

1998 • 2,622 citations

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy

1992 • 2,084 citations

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

1999 • 1,858 citations

Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites

1997 • 1,808 citations

Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription

2000 • 1,658 citations

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1997 • 1,641 citations

Tamoxifen in the Treatment of Breast Cancer

1998 • 1,295 citations

Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer

1992 • 1,139 citations

The Estrogen Receptor β-Isoform (ERβ) of the Human Estrogen Receptor Modulates ERα Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens1

1999 • 1,055 citations

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

2001 • 1,019 citations

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

2000 • 990 citations

ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS

1989 • 932 citations

The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture.

1976 • 820 citations

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1971 • 692 citations

Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial

2001 • 678 citations

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

1998 • 647 citations

Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial

2001 • 634 citations

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

1994 • 614 citations

After the Trial at Leicester

1981 • 545 citations

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

2000 • 531 citations

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.

1992 • 468 citations

A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATS

1967 • 456 citations

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

2002 • 446 citations

Estrogen receptors and breast cancer response to adrenalectomy.

1971 • 434 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

1998 • 421 citations

Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.

1988 • 420 citations

Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.

1990 • 419 citations

Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women

1991 • 380 citations

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

1976 • 377 citations

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

1973 • 373 citations

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

1992 • 360 citations

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1995 • 351 citations

Oral penicillin in gonorrhoea.

1946 • 348 citations

Adjuvant tamoxifen in the management of operable breast cancer : Scottish Trial

1987 • 344 citations

Structural Insights into the Mode of Action of a Pure Antiestrogen

2001 • 342 citations

Effects of anti-estrogens on bone in castrated and intact female rats

1987 • 329 citations

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

2000 • 318 citations

STEROIDAL PURE ANTIOESTROGENS

1987 • 313 citations

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

2001 • 300 citations

Growth Regulation of Estrogen Receptor-Negative Breast Cancer Cells Transfected With Complementary DNAs for Estrogen Receptor

1992 • 263 citations

Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.

1989 • 249 citations

STRUCTURE-ACTIVITY RELATIONSHIPS OF ANTI-OESTROGENS WITH REGARD TO INTERACTION WITH 17β-OESTRADIOL IN THE MOUSE UTERUS AND VAGINA

1971 • 211 citations

The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue

1991 • 201 citations

Effects of Tamoxifen on Spinal Bone Density in Women With Breast Cancer

1989 • 197 citations

Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor

1975 • 186 citations

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

1988 • 180 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

1998 • 171 citations

EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium

1999 • 163 citations

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

1998 • 162 citations

The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain

1994 • 152 citations

Selective estrogen receptor modulation: a personal perspective.

2001 • 151 citations

ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL

1987 • 145 citations

3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats

1994 • 144 citations

Species-specific pharmacology of antiestrogens: role of metabolism.

1987 • 131 citations

The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole

1988 • 130 citations

LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

1998 • 129 citations

Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis

1999 • 128 citations

Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.

1990 • 127 citations

The Brighton resuscitation ambulances: a continuing experiment in prehospital care by ambulance staff.

1976 • 127 citations

The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.

1998 • 122 citations

New biospecific adsorbents for the purification of estradiol receptor.

1978 • 120 citations

Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.

2000 • 110 citations

243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma model

1974 • 107 citations

THE INDUCTION OF OVULATION BY TAMOXIFEN

1973 • 104 citations

Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor

1997 • 104 citations

Molecular Mechanism of Action at Estrogen Receptor α of a New Clinically Relevant Antiestrogen (GW7604) Related to Tamoxifen**This work was supported by NIH CA-56143 (to V.C.J.); Fundaçao Coordenaçao de Aperfeiçoamento de Pessoal de Nível Superior, (CAPES) Scholarship, Brazil (to R.D.); the U.S. Army Medical Research and Material Command Breast Cancer Research Program, DAMD17–96-16169 (to H.L.); the generosity of the Lynn Sage Breast Cancer Research Foundation of Northwestern Memorial …

2001 • 92 citations

A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.

1995 • 82 citations

Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.

2001 • 73 citations

Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer

2001 • 72 citations

SYNTHETIC ŒSTROGENS IN MAMMARY CANCER

1949 • 69 citations

Inhibition of the Uterotropic Activity of Estrogens and Antiestrogens by the Short Acting Antiestrogen LY117018*

1983 • 66 citations

The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor

1998 • 65 citations

The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.

1999 • 65 citations

OOPHORECTOMY IN CANCER OF THE BREAST

1902 • 62 citations

Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

2000 • 59 citations

Possible mechanisms in the emergence of tamoxifen-resistant breast cancer

1995 • 55 citations

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women.

2001 • 55 citations

Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.

2001 • 50 citations

Tamoxifen: a personal retrospective

2000 • 43 citations

Regulation of Prolactin Synthesis in Vitro by Estrogenic and Antiestrogenic Derivatives of Estradiol and Estrone*

1989 • 40 citations

A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog

1995 • 34 citations

Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial.

1986 • 29 citations

Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens

1981 • 20 citations

The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal (PM) women

2002 • 11 citations